Retinopathy of Prematurity (ROP)NCT04506619
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
An observational study of Retinopathy of Prematurity (ROP) and Intraventricular Hemorrhage, run by Oak Hill Bio Ltd at 8 sites in 3 countries.
Trial summary
The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group. Read more about this study
- Who is it for?
- Ages 12 to 24 months
- Conditions the study is for
- Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia
- How many people
- 26 participants
- Where
- 8 sitesin 3 countries
- Study dates
- 9 Sep 2020to 5 Aug 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 24 months
- All sexes
- No healthy volunteers
- Child
Study population: Participants who previously received SHP607 or standard neonatal care in Study SHP607-202 (NCT03253263) are planned to be enrolled in Study SHP607-203.
Who may be able to join
- Participants who were randomized into Study SHP607-202 (NCT03253263). Participants who were randomized, but did not complete Study SHP607-202 (NCT03253263) must be at least 12 months CA.
- Written informed consents (and assents, if applicable) must be signed and dated by the participant's parent(s)/legally authorized representative(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC).
Who cannot join
- Participants are excluded from the study if the participant or participant's parent(s)/legally authorized representative(s) is/are unable to comply with the protocol or is/are unlikely to be available for long-term follow-up as determined by the investigator.
Trial locations and contacts
8 sites in 3 countries.
8 sites in 3 countries
United States4 sites
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Italy3 sites
Azienda Ospedaliera Universitaria Careggi
Florence, 50134
Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN
Genova, 16147
Presidio Ospedaliero Di Treviso Ca' Foncello
Treviso, 31100
United Kingdom1 site
Ashford and St. Peter's Hospitals NHS Trust - St. Peter*s Hospital
Chertsey, Surrey, KT16 0PZ
About this study
Official title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.
Read the detailed description
In this long-term follow-up study, participants who enrolled in SHP607-202 (NCT03253263) will be followed from 12 months corrected age (CA) through 60 months CA. Participants will not receive any investigational product in this study.
- Conditions
- Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
- Being tested
- No Intervention
- Medical subject headings
- Retinopathy of Prematurity, Bronchopulmonary Dysplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No InterventionOther
This is a non-interventional study.
| Study group | Role | What they receive |
|---|---|---|
| SHP607 250 mcg/kg/24 hours | Participants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. Receives: Other: No Intervention | |
| SHP607 400 mcg/kg/24 hours | Participants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. Receives: Other: No Intervention | |
| Standard Neonatal Care | Participants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. Receives: Other: No Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Emergency Room Visits
Number of emergency room visits associated with a respiratory diagnosis will be reported.
Measured: 12 months CA through 60 months CA
Number of Hospitalizations
Number of hospitalizations associated with a respiratory diagnosis will be reported.
Measured: 12 months CA through 60 months CA
Incidence of Signs and Symptoms of Respiratory Disease
Incidence of signs and symptoms of respiratory disease (yes/no) is assessed by recording episodes of wheezing, coughing, and respiratory medication.
Measured: 12 months CA through 60 months CA
Number of Days of Respiratory Medication Use
Number of days of respiratory medication use (for example, bronchodilators, steroids, leukotriene inhibitors, diuretics) will be reported.
Measured: 12 months CA through 60 months CA
Total Number of Days on Home Respiratory Technology use
Total number of days on home respiratory technology use (for example, home oxygen, continuous positive airway pressure [CPAP], tracheostomy) will be reported.
Measured: 12 months CA through 60 months CA
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
Measured: 12 months CA through 60 months CA
Secondary outcomes (18)
Growth Parameters: Body Weight
Body weight is measured in kilograms (kg) without shoes and with light clothing using a calibrated scale.
Measured: At 12, 24, and 60 months CA
Growth Parameters: Body Length
Body length is a supine measurement from the top of the head to the sole of the foot with the participant lying on the back with hips and knees extended.
Measured: At 12 and 24 months CA
Growth Parameters: Height
Height is a measure of participant from head to foot (standing measure). A stadiometer should be utilized for measurement of height.
Measured: At 60 months CA
Growth parameters: Head circumference
Head circumference or occipital frontal circumference is measured over the occiput and just above the supraorbital ridge, which is the largest circumference of the head.
Measured: At 12 and 24 months CA
Physical Development as Assessed by Physical Examination
Physical examinations will include a review of the participant's general appearance.
Measured: At 12, 24, and 60 months CA
Physical Development as Assessed by Neurological Examination for Assessment of Cerebral Palsy
Neurological examination for the diagnosis of cerebral palsy (CP) will be conducted. Neurologic examinations for the diagnosis of CP will be conducted by physicians including assessment of motor function, strength and development, muscle tone, and postural and movement abnormalities.
Measured: At 12, 24, and 60 months CA
Physical Development as Assessed by Visual Acuity
Visual acuity is a measure of how well a participant sees at different distances. It will be categorized as the following: normal (measurable acuity greater than or equal to [>=] 20/40); below normal (20/200 less than or equal to [<=] measurable acuity <20/40); poor (measurable acuity <=20/200); blind/low vision (only the ability to detect the 2.2 centimeter [cm] wide stripes on the low-vision Teller acuity card and at any location in the visual field).
Measured: At 12, 24, and 60 months CA
Cognitive Development Assessed by Bayley Scales of Infant and Toddler Development (BSID-III)
The BSID-III will be used to assess cognitive, motor, and language skills, and is applicable to children aged 1-42 months. The BSID-III is an assessment tool designed to measure a young child's skills in the 3 core areas of development: cognitive, language, and motor. There are 5 subscales, the cognitive subscale (Score range: 55-145) stands alone while the 2 language subscales (expressive and receptive) combine to make a total language score (Range: 47-153) and the 2 motor subtests (fine and gross motor) form a combined motor scale (Range: 46-154). A positive value indicates improvement.
Measured: At 24 months CA
Cognitive Development Quotient Assessed by Kyoto Scale of Psychological Development (KSPD)
KSPD is a alternative scale to the BSID and used to assess cognitive, motor, and language skills at Japan sites only. The KSPD is a validated neurodevelopmental outcome assessment that is standardized for Japanese children and has been evaluated in comparison to BSID in the assessment of developmental characteristics of very low birth weight Japanese infants. The KSPD is designed to measure a young child's skills in three domains of development: Cognitive-Adaptive (non-verbal reasoning or visuospatial perception), Language-Social (interpersonal relationships, socialization, verbal abilities), and Postural-Motor (fine and gross motor functions). The scale consists of 328 items covering a Cognitive-Adaptive area, Language-Social area, and Postural-Motor area. For each of the three areas, a sum score is converted to a Developmental Quotient (dividing the developmental age by the chronological age and then multiplying the quotient by 100). A positive value indicates improvement.
Measured: At 24 months CA
Cognitive Development Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI)
The WPPSI is a measure of general cognitive development in children that has components of both verbal and non-verbal tasks. It is applicable to preschoolers and young children aged 2 years +6 months to 7 years +7 months, and is a direct assessment of a child's cognitive skills. The standard score For the WPPSI ranges from Below 70 (extremely low) to above 130 (very superior).
Measured: At 60 months CA
Gross Motor Function Assessed by Gross Motor Function Measure-88 (GMFM-88)
The GMFM-88 item scores is used to calculate a domain-specific percent score for each of the 5 GMFM-88 dimensions, which are the following: Lying and rolling; Sitting; Crawling and kneeling; Standing; Walking, running, and jumping. Each of the 88 items is rated on a 4-point scale: 0=does not initiate; 1=initiates; 2=partially completes; and 3=completes. The GMFM-88 total scores range from 0% (no mobility) to a score of 100%. The test is considered to be appropriate for children whose motor skills are at or below those of a 5-year-old child without any motor disability. The GMFM-88 will be administered at 24 months CA. GMFM-88 Sections D (Standing) and E (Walking, Running and Jumping) only will be administered at 5 years CA.
Measured: At 24 and 60 months CA
Childhood Behavior Assessed by Vineland Adaptive Behavior Scales (VABS-III)
The VABS-III test measures adaptive behaviors, including the ability to cope with environmental changes, to learn new everyday skills, and to demonstrate independence. This test measures the following 4 key domains: communication, daily living skills, socialization, and motor skills. The score ranges from 20 to 140 on which higher scores indicate a higher level of better behavior.
Measured: At 24 and 60 months CA
Childhood Behavior Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-V)
The ADHD-RS-V measures the behaviors of children with Attention-Deficit/Hyperactivity Disorder (ADHD). It consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-V criteria. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0-54. The 18 items are grouped into 2 subscales: hyperactivity-impulsivity (even numbered items 2-18) and inattention ("inattentiveness") (odd numbered items 1-17).
Measured: At 60 months CA
Childhood Behavior Assessed by Social Communication Questionnaire (SCQ)
The SCQ is a brief instrument that helps evaluate communication skills and social functioning in children that can be used for screening for autism or autism spectrum disorders (ASD) in the general population. The score ranges from 0 to 39, with a cut off of greater than (>) 15 indicating ASD.
Measured: At 60 months CA
Health Related Quality of Life (HRQoL) Assessed by the Pediatric Quality of Life Inventory (PedsQL) Scales
HRQoL will be assessed via the validated Pediatric Quality of Life Inventory (PedsQL) Scales appropriate for the child's age of development. The following scales will be used in this study: Infant Scale for ages 13-24 months (45 Items); Toddler Scale for 2-4 years of age (21 Items); Young Child Scale for 5-7 years of age (23 Items). Scores are transformed to a 0 to 100 scale. Higher scores indicate better quality of life.
Measured: At 24, 36, 48, and 60 months CA
Health Status Measured by the Health Utilities Index 2/3
The Health Utilities Index (HUI) is a family of generic health profiles and preference-based systems used for measuring health status, reporting HRQoL, and producing utility scores. The HUI 2/3 system contains a number of attributes/domains to classify the level of health status. Each attribute or domain (eg, mobility, cognition, emotion or pain) is rated on a 5-point ordinal scale to indicate the severity level, ranging from 1-5 (higher numbers indicating a more severe level).
Measured: At 60 months CA
Healthcare Resource Utilization
Healthcare resource utilization is measured by the number of in-patient and outpatient visits, including emergency room visits and visits to specialists.
Measured: 12 months CA through 60 months CA
Number of Participants With Targeted Medical Events and Fatal Serious Adverse Events (SAEs)
Targeted medical events are intracranial hypertension, any abnormality of glucose metabolism (eg, hypoglycemia, hyperglycemia, and diabetes), tonsillar hypertrophy (based on tonsil examination [part of the physical examination]), and increased cardiac size. A serious adverse event (SAE) is defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome is fatal/results in death, is life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event.
Measured: 12 months CA through 60 months CA
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2020
- Study start9 Sep 2020
- Primary completion5 Aug 2022
- Study completion5 Aug 2022
Why it stopped: As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinopathy of Prematurity (ROP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oak Hill Bio Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04506619
- Sponsor's protocol ID
- SHP607-203
- Other IDs
- 2020-002726-84
- Status last verified
- Apr 2022
- First submitted
- 27 Jul 2020
- Last updated
- 24 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: De-identified individual participant data from this particular study will not be shared in order to minimize the risk that individual patients could be reidentified, given that there are limited numbers of study participants at each study site per year.
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
- ClinicalTrials.gov ID
- NCT04506619
- Acronym / sponsor ID
- SHP607-203
- Conditions
- Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Oak Hill Bio LtdIndustry (pharma, biotech, devices)
- Study start
- 9 Sep 2020 (actual)
- Primary completion
- 5 Aug 2022 (actual)
- Study completion
- 5 Aug 2022 (actual)
- First posted
- 10 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate long-term safety and efficacy outcomes following previously administered short-term exposure to SHP607, as compared to a standard neonatal care group.
Detailed description
In this long-term follow-up study, participants who enrolled in SHP607-202 (NCT03253263) will be followed from 12 months corrected age (CA) through 60 months CA. Participants will not receive any investigational product in this study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| SHP607 250 mcg/kg/24 hours | – | Other: No InterventionParticipants who received 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. |
| SHP607 400 mcg/kg/24 hours | – | Other: No InterventionParticipants who received 400 mcg/kg/24 hours in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. |
| Standard Neonatal Care | – | Other: No InterventionParticipants who received standard neonatal care in the previous study SHP607-202 (NCT03253263) will be followed into this long-term study SHP607-203. |
Who may qualify
- Ages
- 12 to 24 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Participants who previously received SHP607 or standard neonatal care in Study SHP607-202 (NCT03253263) are planned to be enrolled in Study SHP607-203.
Key inclusion criteria (2 listed)
- Participants who were randomized into Study SHP607-202 (NCT03253263). Participants who were randomized, but did not complete Study SHP607-202 (NCT03253263) must be at least 12 months CA.
- Written informed consents (and assents, if applicable) must be signed and dated by the participant's parent(s)/legally authorized representative(s) prior to any study-related procedures. The informed consent and any assents for underage parents must be approved by the institutional review board (IRB)/independent ethics committee (IEC).
Key exclusion criteria (1 listed)
- Participants are excluded from the study if the participant or participant's parent(s)/legally authorized representative(s) is/are unable to comply with the protocol or is/are unlikely to be available for long-term follow-up as determined by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No InterventionThis is a non-interventional study. | Other | SHP607 250 mcg/kg/24 hours, SHP607 400 mcg/kg/24 hours, Standard Neonatal Care |
Primary outcome
Number of Emergency Room Visits
Time frame: 12 months CA through 60 months CA
Number of emergency room visits associated with a respiratory diagnosis will be reported.
Number of Hospitalizations
Time frame: 12 months CA through 60 months CA
Number of hospitalizations associated with a respiratory diagnosis will be reported.
Incidence of Signs and Symptoms of Respiratory Disease
Time frame: 12 months CA through 60 months CA
Incidence of signs and symptoms of respiratory disease (yes/no) is assessed by recording episodes of wheezing, coughing, and respiratory medication.
Number of Days of Respiratory Medication Use
Time frame: 12 months CA through 60 months CA
Number of days of respiratory medication use (for example, bronchodilators, steroids, leukotriene inhibitors, diuretics) will be reported.
Total Number of Days on Home Respiratory Technology use
Time frame: 12 months CA through 60 months CA
Total number of days on home respiratory technology use (for example, home oxygen, continuous positive airway pressure [CPAP], tracheostomy) will be reported.
Number of Participants With Adverse Events (AEs)
Time frame: 12 months CA through 60 months CA
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
18 secondary outcomes
Growth Parameters: Body Weight
Time frame: At 12, 24, and 60 months CA
Growth Parameters: Body Length
Time frame: At 12 and 24 months CA
Growth Parameters: Height
Time frame: At 60 months CA
Growth parameters: Head circumference
Time frame: At 12 and 24 months CA
Physical Development as Assessed by Physical Examination
Time frame: At 12, 24, and 60 months CA
Physical Development as Assessed by Neurological Examination for Assessment of Cerebral Palsy
Time frame: At 12, 24, and 60 months CA
Physical Development as Assessed by Visual Acuity
Time frame: At 12, 24, and 60 months CA
Cognitive Development Assessed by Bayley Scales of Infant and Toddler Development (BSID-III)
Time frame: At 24 months CA
Cognitive Development Quotient Assessed by Kyoto Scale of Psychological Development (KSPD)
Time frame: At 24 months CA
Cognitive Development Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI)
Time frame: At 60 months CA
Gross Motor Function Assessed by Gross Motor Function Measure-88 (GMFM-88)
Time frame: At 24 and 60 months CA
Childhood Behavior Assessed by Vineland Adaptive Behavior Scales (VABS-III)
Time frame: At 24 and 60 months CA
Childhood Behavior Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS-V)
Time frame: At 60 months CA
Childhood Behavior Assessed by Social Communication Questionnaire (SCQ)
Time frame: At 60 months CA
Health Related Quality of Life (HRQoL) Assessed by the Pediatric Quality of Life Inventory (PedsQL) Scales
Time frame: At 24, 36, 48, and 60 months CA
Health Status Measured by the Health Utilities Index 2/3
Time frame: At 60 months CA
Healthcare Resource Utilization
Time frame: 12 months CA through 60 months CA
Number of Participants With Targeted Medical Events and Fatal Serious Adverse Events (SAEs)
Time frame: 12 months CA through 60 months CA
Results and safety
The study was stopped early (reason given: As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2023.
- Individual participant dataSharing planned: No. De-identified individual participant data from this particular study will not be shared in order to minimize the risk that individual patients could be reidentified, given that there are limited numbers of study participants at each study site per year.
Related trials for Retinopathy of Prematurity (ROP)
RecruitingObservational study
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Retinopathy of Prematurity, Preterm Infants
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
RecruitingObservational study
Imaging Retinal Vasculature in Infant Eyes
Retinopathy of Prematurity
RecruitingPhase 1
Safety, PK and PD of FLQ-101 in Premature Neonates
Retinopathy of Prematurity (ROP)
Recruiting
Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care
Retinopathy of Prematurity (ROP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
8 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinopathy of Prematurity (ROP) and Intraventricular Hemorrhage, run by Oak Hill Bio Ltd at 8 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in United States, Italy, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Emergency Room Visits (time frame: 12 months CA through 60 months CA). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2023.